柴胡皂苷A的药理活性和作用机制研究现状及进展

Advances on the pharmacological activity and mechanism of saikosaponin A

摘要:

柴胡皂苷A (Saikosaponin A, SSA) 在中华人民共和国药典 (国家药典委员会2020年版) 中被规定为评价柴胡质量的标记化合物之一。目前对于柴胡及其方剂的临床应用已经比较广泛，但是对于其主要活性成分SSA的药理活性和作用机制的研究仍处于探索阶段。研究显示SSA在体内外均具有生物活性，尤其是在抗炎、抗肿瘤、免疫调节、神经调节与抗病毒等方面。本文旨在结合文献资料深入探讨SSA的体内外药理活性及作用机制，为其今后的进一步开发与临床应用提供参考。

Abstract:

Saikosaponin A (SSA) is specified as one of the labeled compounds for evaluating the quality of Bupleurum in the Pharmacopoeia of the People's Republic of China (the 2020 edition of the Chinese Pharmacopoeia Commission). Since its discovery, SSA has been found to play an important role in treating diverse diseases via a variety of mechanisms. This review summarizes the current research status and prospects of activities of SSA, providing novel insights into the limitations of current studies. In addition, it discusses whether SSA can be applied in clinical therapy and the possible mechanisms by which SSA may facilitate therapy. The research is significant to understand the potentials of SSA in the development of SSA-based therapeutic strategies and clinical practice.